VaxThera
VaxThera is a Colombian science-based biotechnology company dedicated to research, development, and production of biologicals and vaccines to contribute to health sovereignty and public health security in Colombia and Latin America. It aims to achieve sanitary independence through innovation and research, with a focus on emerging and tropical diseases, and is committed to building technological and scientific capabilities in the region.
Industries
Nr. of Employees
small (1-50)
VaxThera
Carrera 64B No. 49A – 30, Medellín, Antioquia
Patents
Products
Universal SARS-CoV-2 vaccine candidate (viral vector platform)
A viral vector–based vaccine candidate developed to provide broad protection against multiple SARS-CoV-2 variants; completed preclinical evaluation and under preparation for early-phase clinical trials.
Vaccine candidates for dengue, chikungunya, yellow fever, influenza and Zika
Pipeline development of vaccines against multiple tropical and re-emerging diseases using viral vector and mRNA platforms up to preclinical stages.
Veterinary vaccine candidates and alternate-route formulations
Development of veterinary vaccine candidates to limit animal-to-human transmission and formulations suitable for oral or intranasal administration.
Universal SARS-CoV-2 vaccine candidate (viral vector platform)
A viral vector–based vaccine candidate developed to provide broad protection against multiple SARS-CoV-2 variants; completed preclinical evaluation and under preparation for early-phase clinical trials.
Vaccine candidates for dengue, chikungunya, yellow fever, influenza and Zika
Pipeline development of vaccines against multiple tropical and re-emerging diseases using viral vector and mRNA platforms up to preclinical stages.
Veterinary vaccine candidates and alternate-route formulations
Development of veterinary vaccine candidates to limit animal-to-human transmission and formulations suitable for oral or intranasal administration.
Services
End-to-end R&D from candidate design to preclinical evaluation using viral vector and mRNA platforms.
Aseptic formulation, fill-and-finish, packaging, and capacity scaling across phased facility expansion.
Establishment and management of partnerships for technology transfer, co-development, and regional commercialization of biologics.
Clinical program management and operational support for early-phase trials and preparation for regulatory submissions.
Creation and dissemination of scientific content and tailored immunization programs to address misinformation and increase vaccine uptake.
End-to-end R&D from candidate design to preclinical evaluation using viral vector and mRNA platforms.
Aseptic formulation, fill-and-finish, packaging, and capacity scaling across phased facility expansion.
Establishment and management of partnerships for technology transfer, co-development, and regional commercialization of biologics.
Clinical program management and operational support for early-phase trials and preparation for regulatory submissions.
Creation and dissemination of scientific content and tailored immunization programs to address misinformation and increase vaccine uptake.
Expertise Areas
- Vaccine research and development
- Bioprocessing and vaccine manufacturing
- Fill-and-finish and aseptic processing
- Regulatory affairs and submissions
Key Technologies
- mRNA vaccine platforms
- Viral vector vaccine platforms
- Aseptic fill-and-finish
- Lyophilization (freeze-drying)
News & Updates
VaxThera will build a 35,000 m² plant in Rionegro, Antioquia, with capacity to produce up to 100 million doses per year, to develop and produce vaccines for COVID-19 and other diseases.
VaxThera has been granted a patent for its COVID-19 vaccine by the United States Patent and Trademark Office (USPTO).
VaxThera will build a 35,000 m² plant in Rionegro, Antioquia, with capacity to produce up to 100 million doses per year, to develop and produce vaccines for COVID-19 and other diseases.
VaxThera has been granted a patent for its COVID-19 vaccine by the United States Patent and Trademark Office (USPTO).